Treatment of Measles in Children
Measles treatment in children is primarily supportive care, with vitamin A supplementation being the only evidence-based specific therapy that reduces morbidity and mortality.
Vitamin A Supplementation - The Only Proven Specific Therapy
All children with severe measles should receive high-dose vitamin A supplementation (400,000 IU for children ≥12 months; 200,000 IU for infants 6-11 months; 100,000 IU for infants <6 months), given orally on two consecutive days 1, 2, 3. This recommendation stands regardless of whether nutritional deficiency is suspected.
Evidence for Vitamin A:
- Two doses of 200,000 IU reduce mortality by 82% in children under 2 years (RR 0.18) 2
- Reduces pneumonia-specific mortality by 67% (RR 0.33) 2
- Shortens duration of pneumonia (6.3 vs 12.4 days) and diarrhea (5.6 vs 8.5 days) 1
- Reduces croup incidence by 47% 2
- Decreases hospital stay by 4+ days 1, 4
Critical caveat: Single-dose vitamin A has NOT shown mortality benefit 2, 3. The two-dose regimen is essential for effectiveness.
Supportive Care Measures
Respiratory Support
- Monitor for pneumonia (most common cause of measles death) 5
- Provide oxygen and respiratory support as needed
- Watch for secondary bacterial infections requiring antibiotics
Hydration and Nutrition
- Maintain adequate hydration, especially with diarrhea
- Continue feeding to prevent malnutrition
- Monitor for dehydration requiring IV fluids
Symptom Management
- Antipyretics for fever control
- Cough management
- Eye care for conjunctivitis
Post-Exposure Prophylaxis (Different from Active Disease Treatment)
While the guidelines 5 extensively discuss post-exposure prophylaxis with MMR vaccine (within 72 hours) or immune globulin (within 6 days), these are preventive measures for exposed contacts, not treatments for children already ill with measles.
For High-Risk Exposed Contacts:
- Immune globulin (IG) 0.25 mL/kg (max 15 mL) for infants ≤12 months, pregnant women, immunocompromised persons 5
- IG 0.5 mL/kg (max 15 mL) for immunocompromised individuals 5
- MMR vaccine within 72 hours for susceptible persons ≥6 months (except immunocompromised/pregnant) 5
Special Populations Requiring Intensive Monitoring
Immunocompromised Children
- Severely immunocompromised and HIV-infected children should receive IG prophylaxis if exposed, regardless of vaccination status 5
- May develop measles without typical rash 5
- Can shed virus for weeks after acute illness 5
- Higher risk for severe complications and death
Infants and Young Children
- Highest risk for complications and death 5
- Require careful monitoring for pneumonia and encephalitis
- Ensure appropriate vitamin A dosing by age
Complications Requiring Aggressive Management
Monitor for:
- Pneumonia (most common complication and cause of death) 5
- Encephalitis (1 in 1,000 cases; often causes permanent brain damage) 5
- Diarrhea (common, increases dehydration risk)
- Otitis media (middle ear infection)
- Death rate: 1-2 per 1,000 cases in the US 5
Infection Control in Healthcare Settings
- Airborne precautions with N-95 masks 6
- Airborne infection isolation room 6
- Patients infectious 4 days before to 4 days after rash onset
- Extremely contagious (among most contagious human diseases) 7
What Does NOT Work
- Single-dose vitamin A: No mortality benefit 2, 3
- Ribavirin and interferon-α: Only small trials/case reports; not standard of care 8
- Antiviral medications: No established role in routine measles treatment 8
Bottom Line Algorithm
- Confirm diagnosis (clinical + IgM serology) 6
- Immediately give vitamin A: 400,000 IU (or age-appropriate dose) on Day 1 and Day 2
- Provide supportive care: hydration, nutrition, respiratory support, fever management
- Monitor closely for complications: pneumonia, encephalitis, severe diarrhea
- Implement airborne isolation to prevent transmission
- Treat complications as they arise (antibiotics for bacterial superinfection, etc.)
The evidence strongly supports that vitamin A is the only specific intervention that changes outcomes in children with active measles disease 1, 2, 3, 4.